MétaCan
Menu
Back to cohort

O-002 Evaluation of the Operating Properties of Candidate Patient Reported Outcomes for Use in Randomized Controlled Trials in Crohn’s Disease

2013· article· en· W2334959221 on OpenAlexaff
Reena Khanna, Geert D’Haens, Brian G. Feagan, William Sandborn, Margaret K. Vandervoort, Guangyong Zou, Robert Rolleri, Enoch Bortey, Craig Paterson, William P. Forbes, Barrett G. Levesque

Bibliographic record

VenueInflammatory Bowel Diseases · 2013
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical TrialsWestern University
Fundersnot available
KeywordsMedicineRandomized controlled trialCrohn's diseaseInternal medicinePhysical therapyInfliximabInflammatory bowel diseasePrednisoneDisease

Abstract

fetched live from OpenAlex

The Crohn’s Disease Activity Index (CDAI), the conventional composite outcome measure used in randomized controlled trials (RCTs), consists of 8 items that evaluate symptoms, signs and laboratory tests. Recently the US FDA has indicated that patient reported outcomes (PROs) should be utilized as, or incorporated into, the primary outcome measure in Crohn’s disease (CD) registration trials in preference to the CDAI. However no validated PROs currently exist. Development and validation of novel PRO instruments is a lengthy process. Therefore, we determined whether the outcomes reported by patients from the CDAI diary card (abdominal pain, stool frequency, general well-being) could be adapted to derive a PRO with favorable operating properties for use in RCTs. Development consisted of 2 phases. In Phase I, data from an RCT1 of rifaximin extended intestinal release therapy were used to identify cut-points that yielded optimum sensitivity and specificity for identification of CDAI –defined remission (score <150). Two item (abdominal pain, stool frequency) and 3 item (2 item plus general well-being) PRO instruments were generated. In Phase II, these instruments were assessed using data from an RCT2 of methotrexate (MTX) induction therapy in active CD for which the primary outcome measure was a CDAI score <150 without prednisone after 16 weeks of therapy. The magnitude of the treatment effect of MTX was estimated using the 2- and 3-item instruments and the CDAI in patients with and without objective evidence of inflammation at baseline (serum orosomucoid concentration >88 mg per deciliter). Figure 1 shows the Receiver Operator Characteristic (ROC) curves for the optimal cut-points for each of the daily average item scores (mean daily stool frequency ≤1.5, mean daily abdominal pain score ≤1, mean daily general well-being score ≤1). Table 1 shows the estimates of effect size of MTX for multiple outcome measures in the 2 patient populations. The estimates of MTX treatment effect were similar for the 2 and 3 item PROs and the CDAI—based outcomes. The largest estimates of the treatment effect were derived when 1) complete withdrawal of prednisone was included in the definition of outcome and 2) patients had objective evidence of inflammation as defined by the presence of an elevated baseline serum concentration of orosomucoid. These data indicate that readily available data derived from patients’ CDAI diary cards may be appropriate for use as a PRO in clinical trials for CD. 1. Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473–81 e4. 2. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292–7.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.301
metaresearch head score (Gemma)0.483
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.699
Threshold uncertainty score0.861

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3010.483
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0040.007
Bibliometrics0.0030.004
Science and technology studies0.0010.002
Scholarly communication0.0040.004
Open science0.0010.003
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0280.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.278
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueInflammatory Bowel DiseasesSame topicInflammatory Bowel DiseaseFrench-language works237,207